Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group - Fisher, CJ; Dhainaut, JF; Opal, SM (JAMA, 1994)
et al.